The treatment group has 79.1% lower chance of death.
Early treatment with hydroxychloroquine: a country-randomized controlled trial
@CovidAnalysis
Many countries either adopted or declined early treatment with HCQ, forming a large country-randomized controlled trial. 2.0 billion people were assigned to the treatment group, and 663 million to the control group. As of August 5, 2020, an average of 37.8/million in the treatment group have died, and 438.5/million in the control group, relative risk 0.086. After adjustments, treatment and control deaths become 78.2/million and 626.6/million, relative risk 0.12. Confounding factors affect this estimate, including varying degrees of spread between countries. Accounting for predicted changes in spread, we estimate a relative risk of 0.21. The treatment group has 79.1% lower chance of death. We examined diabetes, obesity, hypertension, life expectancy, population density, urbanization, testing level, and intervention level, which do not account for the effect observed. |
